The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours
| dc.rights.license | open | en_US |
| hal.structure.identifier | Université de Bordeaux [UB] | |
| dc.contributor.author | HAIK, Laura | |
| dc.contributor.author | GONTHIER, Aurore | |
| dc.contributor.author | QUIVY, Amandine | |
| dc.contributor.author | GROSS-GOUPIL, Marine | |
| dc.contributor.author | VEILLON, Remi | |
| hal.structure.identifier | Université de Bordeaux [UB] | |
| dc.contributor.author | FRISON, Eric | |
| dc.contributor.author | RAVAUD, Alain | |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation [ImmunoConcept] | |
| dc.contributor.author | DOMBLIDES, Charlotte | |
| hal.structure.identifier | Université de Bordeaux [UB] | |
| dc.contributor.author | DASTE, Amaury | |
| dc.date.accessioned | 2022-11-14T15:35:28Z | |
| dc.date.available | 2022-11-14T15:35:28Z | |
| dc.date.created | 2021-09-22 | |
| dc.date.issued | 2021-09-22 | |
| dc.identifier.issn | 0284-186X (print) 1651-226X (online) | en_US |
| dc.identifier.other | https://www.tandfonline.com/doi/suppl/10.1080/0284186X.2021.1978540 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/170256 | |
| dc.description.abstractEn | Background : Evidence suggests that sarcopenia is a significant predictive factor of worst outcomes and treatment-associated toxicities in patients with metastatic solid tumours. The aim of this study was to explore the relationship between low muscle mass and clinical outcomes and immune-related severe toxicities (IrST) in patients treated with immune checkpoint inhibitors (ICIs). Methods : A retrospective cohort of 261 consecutive metastatic solid tumour patients treated with ICIs were included in our study. Low muscle mass was defined as skeletal muscle index <41 cm2/m2 for females and <43 cm2/m2 for males if body mass index (BMI) <25 kg/m2 or <53 cm2/m2 if BMI ≥ 25 kg/m2. Severe toxicities (ST), including grade III-IV toxicities and side effects leading to treatment interruption, were recorded. Results : The majority of patients (n = 179; 69%) included in this study had metastatic lung cancer. The prevalence of low muscle mass was 47%. The median progression-free survival (PFS) was 32.2 weeks for low muscle mass patients and 24.3 weeks for non-low muscle mass patients (adjusted HR, 0.80; 95% CI, 0.60–1.055; p = 0.11). For low muscle mass and non-low muscle mass lung cancer patients, median PFS was 24.0 weeks and 18.8 weeks (adjusted HR, 0.70; 95% CI, 0.50–0.98; p = 0.04) and median overall survival was 50.7 weeks and 41.1 weeks (adjusted HR, 0.77; 95% CI, 0.54–1.10, p = 0.15) respectively. Immune-related severe toxicities occurred in 3.3% and 9.4% of low muscle mass and non-low muscle mass patients respectively (adjusted OR, 0.69; 95% CI: 0.31–1.49; p = 0.35). Conclusion : No difference in outcomes and safety was observed for low muscle mass and non-low muscle mass patients treated with ICIs. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Immune checkpoint inhibitors | |
| dc.subject.en | Immune-related severe toxicity | |
| dc.subject.en | Immunotherapy | |
| dc.subject.en | Low muscle mass | |
| dc.title.en | The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1080/0284186X.2021.1978540 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | en_US |
| dc.identifier.pubmed | 34549686 | en_US |
| bordeaux.journal | Acta Oncologica | en_US |
| bordeaux.page | 1597-1603 | en_US |
| bordeaux.volume | 60 | en_US |
| bordeaux.hal.laboratories | ImmunoConcEpT - UMR 5164 | en_US |
| bordeaux.issue | 12 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Acta%20Oncologica&rft.date=2021-09-22&rft.volume=60&rft.issue=12&rft.spage=1597-1603&rft.epage=1597-1603&rft.eissn=0284-186X%20(print)%201651-226X%20(online)&rft.issn=0284-186X%20(print)%201651-226X%20(online)&rft.au=HAIK,%20Laura&GONTHIER,%20Aurore&QUIVY,%20Amandine&GROSS-GOUPIL,%20Marine&VEILLON,%20Remi&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||